Recent Posts

More Posts

Overview Many people have tried to use machine learning in various implementations in order to forecast trends and trade securities. John Fawcett and Alex Izydorczyk, among others have discussed the topic on the Quantopian community. Here we’ll walk through a comparison of a simple classification strategy and compare results between different classifiers, using Quantopian’s Zipline backtester to help prototype the strategy. Feature Generation For any security \(s_k\), let vector

CONTINUE READING

A new revolution is about to start - get in on the ground floor! Well, it’s been a few months since the last posting on the huge unmet clinical need for microbiome analytics. And the market map still looks roughly the same. The genomic revolution has been happening for 15+ years. Nowadays, genomics is prevalent in almost all major areas of biological science. However, we are still in the early days of the microbiome revolution.

CONTINUE READING

People watching pharma companies and the drug development process (this includes investors/VCs, academia and the general public) from the outside will seldom think about this unmet need. The Problem If you’re a scientist, you don’t participate in the upside but you participate a lot in the downside in the case a drug fails to make it past trials and onto the market.. This isn’t exactly a secret (see interview: Vivek Ramaswamy, Roivant Sciences CEO), but is something casual biology enthusiasts or scientists in academia may not appreciate.

CONTINUE READING

People watching pharma companies and the drug development process (this includes investors/VCs, academia and the general public) from the outside will seldom think about this unmet need. The Problem If you’re a scientist, you don’t participate in the upside but you participate a lot in the downside in the case a drug fails to make it past trials and onto the market.. This isn’t exactly a secret (see interview: Vivek Ramaswamy, Roivant Sciences CEO), but is something casual biology enthusiasts or scientists in academia may not appreciate.

CONTINUE READING

Roku (NASDAQ: ROKU) Date written: Feb 15, 2018 Current price: $45 Price target: $20-25 (45-55% gain) Time frame: 6-12 months Recommendation What: SHORT with price target of $20/share (50% to gain). Time frame: 6-18 months. Why: Overly ambitious user growth estimates Inferior hardware product Limited potential for company to cut costs Catalysts: Potential earnings miss (2/21/18) Missed earnings will cause a sell-off IPO lockup period ends March 2018 => stock price will drop Series B converted shares will get sold off => stock price will drop Risks:

CONTINUE READING

Projects

Open Science Organization

Open Science Organization - the blockchain solution for fair, transparent, quality science

Biohacker Guide

I was an editor and writer for the Biohacker Guide, hosted on Nootrobox’s website.

Deep Learning for Medicine

Deep learning for medicine: readmission prediction, early disease detection

Predictive Modeling System

Predictive modeling pipeline for healthcare. Applications for readmission prediction.

Medcyclops

Wearable head-up display for image-guided surgery.

Selected Publications

Recent Publications

Recent & Upcoming Talks

Teaching

I am a teaching instructor for the following courses at GT:

  • CSE 6250: Healthcare Analytics (2x)
  • VIP team: Predictive Health

Contact